Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Cardiovascular Translational Research
Published in: Journal of Cardiovascular Translational Research 3/2018

Open Access 01-06-2018 | Original Article

Serum MMP-9 Diagnostics, Prognostics, and Activation in Acute Coronary Syndrome and Its Recurrence

Authors: Laura Lahdentausta, Jaakko Leskelä, Alina Winkelmann, Taina Tervahartiala, Timo Sorsa, Erkki Pesonen, Pirkko J. Pussinen

Published in: Journal of Cardiovascular Translational Research | Issue 3/2018

Login to get access

Abstract

Matrix metalloproteinase (MMP)-9 is crucial in atherosclerotic plaque rupture and tissue remodeling after a cardiac event. The balance between MMP-9 and endogenous inhibitor, tissue inhibitors of matrix metalloproteinase 1 (TIMP-1), is important in acute coronary syndrome (ACS). This is an age- and gender-matched case-control study of ACS (N = 669). Patients (45.7%) were resampled after recovery, and all were followed up for 6 years. The molecular forms of MMP-9 were investigated by gelatin zymography. Diagnostically, MMP-9 and the MMP-9/TIMP-1 molar ratio were associated with ACS (OR 5.81, 95% CI 2.65–12.76, and 4.96, 2.37–10.38). The MMP-9 concentrations decreased 49% during recovery (p < 0.001). The largest decrease of these biomarkers between acute and recovery phase (ΔMMP-9) protected the patients from major adverse cardiac events, especially the non-fatal events. The fatal events were associated with in vitro activatable MMP-9 levels (p = 0.028). Serum MMP-9 and the MMP-9/TIMP-1 molar ratio may be valuable in ACS diagnosis and prognosis. High serum MMP-9 activation potential is associated with poor cardiovascular outcome.
Appendix
Available only for authorised users
Literature
1.
Ross, R. (1999). Atherosclerosis—an inflammatory disease. The New England Journal of Medicine, 340(2), 115–126.CrossRefPubMed
2.
Libby, P., Ridker, P. M., Hansson, G. K., & Leducq Transatlantic Network on Atherothrombosis. (2009). Inflammation in atherosclerosis: from pathophysiology to practice. Journal of the American College of Cardiology, 54(23), 2129–2138.CrossRefPubMedPubMedCentral
3.
Packard, R. R., & Libby, P. (2008). Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clinical Chemistry, 54(1), 24–38.CrossRefPubMed
4.
Tayebjee, M. H., Lip, G. Y., & MacFadyen, R. J. (2005). Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance. Current Medicinal Chemistry, 12(8), 917–925.CrossRefPubMed
5.
Van Doren, S. R. (2015). Matrix metalloproteinase interactions with collagen and elastin. Matrix Biology, 44-46, 224–231.CrossRefPubMed
6.
Arpino, V., Brock, M., & Gill, S. E. (2015). The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biology, 44-46, 247–254.CrossRefPubMed
7.
Bannikov, G. A., Karelina, T. V., Collier, I. E., Marmer, B. L., & Goldberg, G. I. (2002). Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. The Journal of Biological Chemistry, 277(18), 16022–16027.CrossRefPubMed
8.
Brew, K., Dinakarpandian, D., & Nagase, H. (2000). Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochimica et Biophysica Acta, 1477(1–2), 267–283.CrossRefPubMed
9.
Yabluchanskiy, A., Ma, Y., Iyer, R. P., Hall, M. E., & Lindsey, M. L. (2013). Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology (Bethesda), 28(6), 391–403.
10.
Grierson, C., Miller, D., LaPan, P., & Brady, J. (2010). Utility of combining MMP-9 enzyme-linked immunosorbent assay and MMP-9 activity assay data to monitor plasma enzyme specific activity. Analytical Biochemistry, 404(2), 232–234.CrossRefPubMed
11.
Kai, H., Ikeda, H., Yasukawa, H., Kai, M., Seki, Y., Kuwahara, F., Ueno, T., Sugi, K., & Imaizumi, T. (1998). Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. Journal of the American College of Cardiology, 32(2), 368–372.
12.
Inokubo, Y., Hanada, H., Ishizaka, H., Fukushi, T., Kamada, T., & Okumura, K. (2001). Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. American Heart Journal, 141(2), 211–217.
13.
Derosa, G., D’Angelo, A., Scalise, F., Avanzini, M.A., Tinelli, C., Peros, E., Fogari, E., & Cicero, A.F. (2007). Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart and Vessels, 22(6), 361–370.
14.
Fukuda, D., Shimada, K., Tanaka, A., Kusuyama, T., Yamashita, H., Ehara, S., Nakamura, Y., Kawarabayashi, T., Iida, H., Yoshiyama, M., et al. (2006). Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. The American Journal of Cardiology, 97(2), 175–180.CrossRefPubMed
15.
Tan, J., Hua, Q., Gao, J., & Fan Z. X. (2008). Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clinical Cardiology, 31(9), 413–418. https://​doi.​org/​10.​1002/​clc.​20254.
16.
Blankenberg, S., Rupprecht, H. J., Poirier, O., Bickel, C., Smieja, M., et al. (2003). Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation, 107(12), 1579–1585.CrossRefPubMed
17.
Pesonen, E., El-Segaier, M., Persson, K., Puolakkainen, M., Sarna, S., Ohlin, H., & Pussinen, P. J. (2009). Infections as a stimulus for coronary occlusion, obstruction, or acute coronary syndromes. Therapeutic Advances in Cardiovascular Disease, 3(6), 447–454.CrossRefPubMed
18.
Pussinen, P. J., Sarna, S., Puolakkainen, M., Öhlin, H., Sorsa, T., & Pesonen, E. (2013). The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence. International Journal of Cardiology, 167(2), 362–368.CrossRefPubMed
19.
20.
Alfakry, H. (2014). Immune and proteolytic events associated with the signs of periodontal and cardiovascular diseases and their treatment. Doctoral dissertation, University of Helsinki. ISBN:978-952-10-9985-4.
21.
Nagase, H., & Brew, K. (2003). Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochemical Society Symposium, 70, 201–212.CrossRef
22.
Sorsa, T., Salo, T., Koivunen, E., Tyynelä, J., Konttinen, Y. T., Bergmann, U., Tuuttila, A., Niemi, E., Teronen, O., Heikkilä, P., Tschesche, H., Leinonen, J., Osman, S., & Stenman, U. H. (1997). Activation of type IV procollagenases by human tumor-associated trypsin-2. The Journal of Biological Chemistry, 272(34), 21067–21074.CrossRefPubMed
23.
Kelly, D., Khan, S. Q., Thompson, M., Cockerill, G., Ng, L. L., Samani, N., & Squire, I. B. (2008). Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. European Heart Journal, 29(17), 2116–2124.CrossRefPubMedPubMedCentral
24.
Hansson, G. (2005). Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine, 352(16), 1685–1695.CrossRefPubMed
25.
Garvin, P., Nilsson, L., Carstensen, J., Jonasson, L., & Kristenson, M. (2008). Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS One, 3(3), e1774.CrossRefPubMedPubMedCentral
26.
Abdelnaseer, M. M., Nervana, M. E., Esmail, E. H., Kamal, M. M., & Elsawy, E. H. (2017). Matrix metalloproteinase-9 and recovery of acute ischemic stroke. Journal of Stroke and Cerebrovascular Diseases, 26, 733–740.CrossRefPubMed
27.
Kobayashi, N., Hata, N., Kume, N., Yokoyama, S., Shinada, T., Tomita, K., Kitamura, M., Shirakabe, A., Inami, T., Yamamoto, M., et al. (2011). Matrix metalloproteinase-9 for the earliest stage acute coronary syndrome. Circulation Journal, 75(12), 2853–2861.CrossRefPubMed
28.
Guzel, S., Serin, O., Guzel, E. C., Buyuk, B., Yilmaz, G., & Güvenen, G. (2013). Interleukin-33, matrixmetalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction. The Korean Journal of Internal Medicine, 28(2), 165–173.CrossRefPubMedPubMedCentral
29.
Peterson, J. T., Li, H., Dillon, L., & Bryant, J. W. (2000). Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovascular Research, 46(2), 307–315.CrossRefPubMed
30.
Cimmino, G., Ragni, M., Cirillo, P., Petrillo, G., Loffredo, F., Chiariello, M., Gresele, P., Falcinelli, E., & Golino, P. (2013). C-reactive protein induces expression of matrix metalloproteinase-9: a possible link between inflammation and plaque rupture. International Journal of Cardiology, 168(2), 981–986.CrossRefPubMed
31.
Opstad, T. B., Pettersen, A. A., Weiss, T. W., Akra, S., Øvstebø, R., Arnesen, H., & Seljeflot, I. (2012). Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clinica Chimica Acta, 413(1–2), 113–120.CrossRef
32.
Li, J., Lu, H., Tao, F., Zhou, H., Feng, G., He, L., & Zhou, L. (2013). Meta-analysis of MMP9-562C/T and the risk of coronary heart disease. Cardiology, 124(1), 53–59.CrossRefPubMed
33.
Vilmi-Kerälä, T., Lauhio, A., Tervahartiala, T., Palomäki, O., Uotila, J., Sorsa, T., & Palomäki, A. (2017). Subclinical inflammation associated with prolonged TIMP-1 upregulation and arterial stiffness after gestational diabetes mellitus: a hospital-based cohort study. Cardiovascular Diabetology, 16(1), 49.CrossRefPubMedPubMedCentral
34.
Hausenloy, D. J., Garcia-Dorado, D., Bøtker, H. E., Davidson, S. M., Downey, J., Engel, F. B., Jennings, R., et al. (2017). Novel targets and future strategies for acute cardioprotection: Position paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research, 113(6), 564–585.CrossRefPubMed
35.
Bencsik, P., Pálóczi, J., Kocsis, G. F., Pipis, J., Belecz, I., Varga, Z. V., Csonka, C., et al. (2014). Moderate inhibition of myocardial matrix metalloproteinase-2 by ilomastat is cardioprotective. Pharmacological Research, 80, 36–42.CrossRefPubMed
36.
Barkho, B. Z., Munoz, A. E., Li, X., et al. (2008). Endogenous matrix metalloproteinase (MMP)-3 and MMP-9 promote the differentiation and migration of adult neural progenitor cells in response to chemokines. Stem Cells, 26, 3139–3149.CrossRefPubMedPubMedCentral
37.
Kupai, K., et al. (2010). Matrix metalloproteinase activity assays: importance of zymography. Journal of Pharmacological and Toxicological Methods, 61(2), 205–209.CrossRefPubMed
38.
Kjeldsen, L., Johnsen, A. H., Sengeløv, H., & Borregaard, N. (1993). Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. The Journal of Biological Chemistry, 268(14), 10425–10432.PubMed
39.
Roy, R., Louis, G., Loughlin, K. R., Wiederschain, D., Kilroy, S. M., Lamb, C. C., Zurakowski, D., & Moses, M. A. (2008). Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clinical Cancer Research, 14(20), 6610–6617.CrossRefPubMedPubMedCentral
40.
Van Wart, H. E., & Birkedal-Hansen, H. (1990). The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proceedings of the National Academy of Sciences of the United States of America, 87(14), 5578–5582.CrossRefPubMedPubMedCentral
41.
Ikeda, M., Maekawa, R., Tanaka, H., Matsumoto, M., Takeda, Y., Tamura, Y., Nemori, R., & Yoshioka, T. (2000). Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography. Clinical Cancer Research, 6(8), 3290–3296.PubMed
42.
DeCoux, A., Lindsey, M. L., Villarreal, F., Garcia, R. A., & Schulz, R. (2014). Myocardial matrix metalloproteinase-2: inside out and upside down. Journal of Molecular and Cellular Cardiology, 77, 64–72.CrossRefPubMed
43.
Jacob-Ferreira, A. L., Kondo, M. Y., Baral, P. K., James, M. N., Holt, A., Fan, X., & Schulz, R. (2013). Phosphorylation status of 72 kDa MMP-2 determines its structure and activity in response to peroxynitrite. PLoS One, 8(8), e71794.CrossRefPubMedPubMedCentral
44.
Bencsik, P., Sasi, V., Kiss, K., Kupai, K., Kolossváry, M., Maurovich-Horvat, P., Csont, T., Ungi, I., Merkely, B., & Ferdinandy, P. (2015). Serum lipids and cardiac function correlate with nitrotyrosine and MMP activity in coronary artery disease patients. European Journal of Clinical Investigation, 45(7), 692–701.CrossRefPubMed
45.
Marx, N., Froehlich, J., Siam, L., Ittner, J., Wierse, G., Schmidt, A., Scharnagl, H., Hombach, V., & Koenig, W. (2003). Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 23(2), 283–288.CrossRefPubMed
46.
Andrade, V. L., Petruceli, E., Belo, V. A., Andrade-Fernandes, C. M., Caetano Russi, C. V., Bosco, A. A., Tanus-Santos, J. E., & Sandrim, V. C. (2012). Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women. Clinical Biochemistry, 45(6), 412–415.CrossRefPubMed
47.
Hopps, E., Lo Presti, R., Montana, M., Noto, D., Averna, M. R., & Caimi, G. (2013). Gelatinases and their tissue inhibitors in a group of subjects with metabolic syndrome. Journal of Investigative Medicine, 61(6), 978–983.CrossRefPubMed
48.
Andrade, V. L., do Valle, I. B., & Sandrim, V. C. (2013). Simvastatin therapy decreases MMP-9 levels in obese women. Journal of Clinical Pharmacology, 53(10), 1072–1077.CrossRefPubMed
49.
Ferretti, G., Bacchetti, T., Banach, M., Simental-Mendía, L. E., & Sahebkar, A. (2016). Impact of statin therapy on plasma MMP-3, MMP-9, and TIMP-1 concentrations. Angiology, 68, 850–862.CrossRef
Metadata
Title
Serum MMP-9 Diagnostics, Prognostics, and Activation in Acute Coronary Syndrome and Its Recurrence
Authors
Laura Lahdentausta
Jaakko Leskelä
Alina Winkelmann
Taina Tervahartiala
Timo Sorsa
Erkki Pesonen
Pirkko J. Pussinen
Publication date
01-06-2018
Publisher
Springer US
Published in
Journal of Cardiovascular Translational Research / Issue 3/2018
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-018-9789-x

Other articles of this Issue 3/2018

Journal of Cardiovascular Translational Research 3/2018 Go to the issue

Review

Retrograde Coronary Venous Infusion as a Delivery Strategy in Regenerative Cardiac Therapy: an Overview of Preclinical and Clinical Data

Original Article

Inhibition of Aortic Valve Calcification by Local Delivery of Zoledronic Acid—an Experimental Study

Original Article

Tirofiban Positively Regulates β1 Integrin and Favours Endothelial Cell Growth on Polylactic Acid Biopolymer Vascular Scaffold (BVS)

Original Article

Effect of Aerobic Exercise on Treg and Th17 of Rats with Ischemic Cardiomyopathy

Original Article

GLP-1 Improves Diastolic Function and Survival in Heart Failure with Preserved Ejection Fraction

Original Article

Association of D-dimer with Plaque Characteristics and Plasma Biomarkers of Oxidation-Specific Epitopes in Stable Subjects with Coronary Artery Disease

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits